

## Retraction in Part: A Genomic Approach to Identify Molecular Pathways Associated with Chemotherapy Resistance

We wish to retract Table 1 and Supplemental Table 1 from our article entitled "A genomic approach to identify molecular pathways associated with chemotherapy resistance," which was published in the October 2008 issue of *Molecular Cancer Therapeutics* (1).

Using previously published annotations for chemotherapy sensitivity in the NCI-60 series of cancer cell lines (2), we performed gene set enrichment analysis on predefined groups of sensitive and resistant NCI-60 cell lines for a range of chemotherapies to identify biological pathways associated with resistance. We purposefully used the annotations for sensitivity and resistance published in the *Nature Medicine* article and applied a complementary computational approach in order to glean biological insight from the differential gene expression. The article upon which our annotations were based has now been retracted (3). After re-examination, the annotations for the cell lines with respect to chemotherapy sensitivity were erroneous. Thus, our manuscript propagates this error and the results in Table 1 and Supplemental Table 1 from our manuscript are invalid.

The majority of the paper reports our work including *in vitro* sensitivity testing for 40 lung cancer cell lines, identification of pathways associated with resistance to tested agents, and functional validation of a lead candidate pathway *in vitro*. These data appear in the remaining Figures 1–7 and Table 2 of the paper and we remain confident in our analysis and findings.

### Richard F. Riedel

<sup>1</sup>Duke Institute for Genome Sciences and Policy, Duke University and  
<sup>2</sup>Division of Medical Oncology, Department of Medicine

### Alessandro Porrello

<sup>1</sup>Duke Institute for Genome Sciences and Policy, Duke University

### Emily Pontzer

<sup>1</sup>Duke Institute for Genome Sciences and Policy, Duke University

### Emily J. Chenette

<sup>1</sup>Duke Institute for Genome Sciences and Policy, Duke University

### David S. Hsu

<sup>1</sup>Duke Institute for Genome Sciences and Policy, Duke University and  
<sup>2</sup>Division of Medical Oncology, Department of Medicine, Duke University

### Bala Balakumaran

<sup>1</sup>Duke Institute for Genome Sciences and Policy, Duke University

### Anil Potti\*

<sup>1</sup>Duke Institute for Genome Sciences and Policy, Duke University and  
<sup>2</sup>Division of Medical Oncology, Department of Medicine, Duke University

\*Former Institute

**Joseph Nevins**

<sup>1</sup>Duke Institute for Genome Sciences and Policy, Duke University and  
<sup>3</sup>Molecular Genetics and Microbiology, Duke University Medical Center,  
Durham, North Carolina

**Phillip G. Febbo\*\***

<sup>1</sup>Duke Institute for Genome Sciences and Policy, Duke University and  
<sup>2</sup>Division of Medical Oncology, Department of Medicine, and <sup>3</sup>Molecular  
Genetics and Microbiology, Duke University Medical Center, Durham, North  
Carolina

\*\*Current Institution

Departments of Medicine and Urology, University of California, San Fran-  
cisco Medical School, San Francisco, CA

**References**

1. Riedel RF, Porrello A, Pontzer E, Chenette EJ, Hsu DS, Balakumaran B, et al. A genomic approach to identify molecular pathways associated with chemotherapy resistance. *Mol Cancer Ther* 2008;7:3141–9.
2. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, et al. Genomic signatures to guide the use of chemotherapeutics. *Nat Med* 2006;12:1294–300.
3. Potti A, Dressman H, Bild A, Riedel R, Chan G, Sayer R, et al. Retraction: Genomic signatures to guide the use of chemotherapeutics. *Nat Med* 2011;17:135.

Published OnlineFirst March 29, 2012.

doi: 10.1158/1535-7163.MCT-12-0210

©2012 American Association for Cancer Research.